Autism: Role of drug treatment and a guided to its use

CNS Drugs

Volumn 8, Issue 3, 1997, Pages 227-236

  Harteveld, Erica M ^a   Buitelaar, Jan K ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Child Psychiatry ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BUSPIRONE; CLOMIPRAMINE; CLONIDINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; NALTREXONE; OPIATE ANTAGONIST; PIMOZIDE; PROPRANOLOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AUTISM; BEHAVIOR THERAPY; DEVELOPMENTAL DISORDER; DRUG EFFICACY; EDUCATION; FAMILY COUNSELING; HUMAN; PRIORITY JOURNAL; REVIEW; SOCIAL SUPPORT;

EID: 0030798299     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708030-00005     Document Type: Review

References (67)

1. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943; 2: 217-50
2. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
4. Bailey A, Philips W, Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J Child Psychol Psychiatry 1996; 37: 89-126
5. Wing L. The definition and prevalence of autism: a review. Eur Child Adolesc Psychiatry 1993; 2: 61-74
6. Lord C, Rutter M. Autism and pervasive developmental disorders. In: Rutter M, Taylor E, Hersov L, editors. Child and adolescent psychiatry: modern approaches. 3rd ed. Oxford: Blackwell Science Ltd, 1994: 569-93
7. Baron-Cohen S, Allen J, Gillberg C. Can autism be detected at 18 months? The needle, the haystack, and the CHAT. Br J Psychiatry 1992; 161: 839-43
8. Gillberg C, Nordin V, Ehlers S. Early detection of autism: diagnostic instruments for clinicians. Eur Child Adolesc Psychiatry 1996; 5: 67-74
9. Schopler E, Reichler RJ, Renner BR. The childhood autism rating scale (CARS) revised. Los Angeles: Western Psychological Services Inc., 1988
10. Lord C, Rutter M, Le Couteur A. Autism diagnostic interviewrevised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Discord 1994; 24: 659-85
11. Lord C, Rutter M, Goode S, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Discord 1989; 19: 185-212
12. Gillberg C, Coleman M. Autism and medical disorders: a review of the literature. Dev Med Child Neurol 1996; 38: 191-202
13. Rutter M, Bailey A, Bolton P, et al. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry 1994; 35: 311-22
14. Rutter M. The treatment of autistic children. J Child Psychol Psychiatry 1985; 26 (2): 193-214
15. Van der Gaag RJ. Multiplex developmental disorder: an exploration of borderlines on the autistic spectrum [thesis]. Utrecht: University of Utrecht, 1993
16. Campbell M, Schopler E. Pervasive developmental disorders. In: Treatments of psychiatric disorders: a task force report of the American Psychiatric Association, Vol 1. Washington, DC: American Psychiatric Association, 1989: 201-17
17. Williams T. A social skills group for autistic children. J Autism Dev Discord 1989; 19: 143-56
18. Mesibov GB. Social skills training with verbal autistic adolescents and adults: a program model. J Autism Dev Discord 1984; 14: 395-404
19. Lovaas OI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol 1987; 55: 3-9
20. McEachin J, Smith T, Lovaas O. Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard 1993; 97: 359-72
21. Campbell M, Schopler E, Cueva JE, et al. Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry 1996; 35 (2): 134-43
22. Andersen LT, Campbell M, Graga DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141: 1195-202
23. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Discord 1989; 19: 227-39
24. Fisher W, Kerbeshian J, Burd L. A treatable language disorder: pharmacological treatment of pervasive developmental disorder. J Dev Behav Pediatr 1986; 7: 73-6
25. Joshi PT, Capozzoli JA, Coyle JT. Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder. Am J Psychiatry 1988; 145: 335-8
26. Gilman JT, Tuchman RF. Autism and associated behavioral disorders: pharmacotherapeutic intervention. Ann Pharmacother 1995; 29: 47-56
27. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous administration. J Am Acad Child Adolesc Psychiatry 1989; 28: 87-92
28. Campbell M, Anderson LT, Green WH, et al. Psychopharmacology. In: Cohen DJ, Donnellan AM, editors. Handbook of autism and pervasive developmental disorders. New York: Wiley & Sons, 1987: 545-65
29. Campbell M, Adams P, Perry R, et al. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 1988; 24: 251-5
30. Naruse H, Nagahata M, Nakane Y, et al. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using cross-over design. Acta Paedopsychiatr 1982; 48: 173-84
31. Ernst M, Magee HJ, Gonzalez NM, et al. Pimozide in autistic children. Psychopharmacol Bull 1992; 28: 187-91
32. Hardan A, Johnson K, Johnson C, et al. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35(11): 1551-6
33. McDougle CJ, Holmes JP, Bronson ME, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36: 685-93
34. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 53-60
35. Anderson GM, Home WC, Chatterjee D, et al. The hyperserotonemia of autism. Ann NY Acad Sci 1990; 600: 331-42
36. Cook EHJ, Leventhal BL, Heller W, et al. Autistic children and their first-degree relatives: relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiatry Clin Neurosci 1990; 2: 268-74
37. McDougle CJ, Price LH, Volkmar FR, et al. Clomipramine in autism: preliminary evidence of efficacy (case study). J Am Acad Child Adolesc Psychiatry 1992; 31: 746-50
38. Sanchez LE, Campbell M, Small AM, et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35 (4): 537-44
39. McDougle CJ, Naylor ST, Cohen DJ, et al. A double blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 1001-8
40. Bregman J, Volkmar F, Cohen DJ. Fluoxetine in the treatment of autistic disorder [abstract]. Proceedings of the 38th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 1991, 52
41. Geller E, Ritvo ER, Freeman BJ. Preliminary observations on the effects of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307: 165-9
42. Ritvo ER, Freeman BJ, Geller E, et al. Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Psychiatry 1983; 22: 549-58
43. Ritvo ER, Freeman BJ, Yuwiler A, et al. Fenfluramine treatment of autism: UCLA collaboration study of 81 patients at nine medical centers. Psychopharmacol Bull 1986; 22: 133-40
44. Schuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull 1986; 22: 148-51
45. Realmuto GM, Jensen J, Klykylo W, et al. Untoward effects of fenfluramine in autistic children. J Clin Psychopharmacol 1986; 6: 350-5
46. Buitelaar JK. Psychopharmacological approaches to childhood psychotic disorders. In: Den Boer JA, Westenberg HGM, van Praag HM, editors. Advances in the neurobiology of schizophrenia. New York: Wiley & Sons, 1995: 429-57
47. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989; 9: 122-5
48. Ratey JJ, Sovner R, Mikkelsen E, et al. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 1989; 50: 382-4
49. Panksepp J. A neurochemical theory of autism. Trends Neurosci 1979; 2: 174-7
50. Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993; 32: 1283-91
51. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995; 34: 223-31
52. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995; 58: 203-15
53. Willemsen-Swinkels SHN, Buitelaur JK, Van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39: 1023-31
54. Willemsen-Swinkels SHN, Buitelaar JK, Nijhof G, et al. Failure of naltrexone to reduce autistic and self-injurious behavior in mentally retarded adults. Arch Gen Psychiatry 1995; 52: 766-73
55. Campbell M, Fish B, David R, et al. Response to triiodothyronine and dextroamphelamine: a study of preschool schizophrenic children. J Autism Child Schizophr 1972; 2: 343-57
56. Bloom AS, Russel LJ, Weisskopf B, et al. Methylphenidate-induced delusional disorder in a child with attention-deficit disorder with hyperactivity (case study). J Am Acad Child Adolesc Psychiatry 1988; 27: 88-9
57. Quintana H, Birmaher B, Sledge D, et al. Use of methylphenidale in the treatment of children with autistic disorder. J Autism Dev Discord 1995; 25 (3): 283-94
58. Aman MG, Marks RE, Turbott SH, et al. Clinical effects of methylphenidate and thioridazine in intellectually sub-average children. J Am Acad Child Adolesc Psychiatry 1991; 30: 246-56
59. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53: 77-82
60. Jaselskis C, Cook EH, Flelchcr KE, et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992; 12: 322-7
61. Ratey JJ, Bemporad J, Sorgi P, et al. Brief report: open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Discord 1987; 17: 439-46
62. Ratey JJ, Mikkelsen E, Sorgi P, et al. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol 1987; 7: 35-41
63. Komoto JM, Usui S, Hirata J. Infantile autism and affective disorder. J Autism Dev Discord 1984; 14: 81-4
64. Kerbeshian J, Burd I, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987; 7: 401-5
65. Buitelaar JK. Self-injurious behavior in retarded children, clinical phenomena and biological mechanisms. Acta Paedopsychiatr 1993; 56: 105-12
66. Gillberg C. The treatment of epilepsy in autism. J Autism Dev Discord 1991; 21: 61-77
67. Plioplys A. Autism: electroencephalographic abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med 1994; 148: 220-2